Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.77 AUD
Change Today 0.00 / 0.00%
Volume 1.7M
SIP On Other Exchanges
As of 1:10 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

sigma pharmaceuticals ltd (SIP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - A$1.00
52 Week Low
12/3/14 - A$0.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sigma pharmaceuticals ltd (SIP) Related Businessweek News

No Related Businessweek News Found

sigma pharmaceuticals ltd (SIP) Details

Sigma Pharmaceuticals Limited engages in the wholesale and distribution of pharmaceutical products to hospitals and retail pharmacies in Australia. It operates approximately 300 pharmacies under the Amcal name; and 150 pharmacies under the Guardian name. The company also offers health management services, including professional advice; and tailored products in the areas of heart health, bones and joints, diabetes, and respiration under the Amcal Max name. In addition, it manages and promotes a range of over the counter private and exclusive label products made available to brand member customers, as well as a generic range of private label products under the Pharmacy Care range. Sigma Pharmaceuticals Limited was founded in 1912 and is headquartered in Rowville, Australia.

Founded in 1912

sigma pharmaceuticals ltd (SIP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$1.7M
Chief Financial Officer
Total Annual Compensation: A$602.8K
Chief Operating Officer
Total Annual Compensation: A$680.9K
Compensation as of Fiscal Year 2015.

sigma pharmaceuticals ltd (SIP) Key Developments

Sigma Pharmaceuticals Ltd. Announces Dividend for the Six Months Ended July 31, 2015, Payable on October 7, 2015

Sigma Pharmaceuticals Ltd. has determined a dividend payable of 2.0 cents per share, with a payment date of 7 October 2015, ex-dividend date of 23 September 2015 and record date of 25 September 2015.

Sigma Pharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Half Year Ended July 31, 2015

Sigma Pharmaceuticals Ltd. announced unaudited consolidated earnings results for the half year ended July 31, 2015. For the period, the company reported sales revenue of AUD 1,674,968,000 compared with AUD 1,502,208,000 for the same period a year ago. EBITDA was AUD 37,146,000 compared with AUD 37,079,000 for the same period a year ago. EBIT was AUD 32,295,000 compared with AUD 33,458,000 for the same period a year ago. Profit before tax was AUD 30,994,000 compared with AUD 32,796,000 for the same period a year ago. Net profit after tax was AUD 18,886,000 compared with AUD 22,394,000 for the same period a year ago. Profit for the period attributable to owners of the company was AUD 18,928,000 or 1.7 cents per diluted share compared with AUD 22,394,000 or 2.1 cents per diluted share for the same period a year ago. Net cash outflow from operating activities was AUD 3,984,000 compared with net cash inflow from operating activities of AUD 18,826,000 for the same period a year ago. Payments for property, plant and equipment and software were AUD 2,805,000 compared with AUD 2,261,000 for the same period a year ago.

Sigma Pharmaceuticals Mulls Acquisitions

Sigma Pharmaceuticals Ltd. (ASX:SIP) intends to make acquisitions. Mark Hooper, Chief Executive Officer, Managing Director of the company said: “The fact that we continue to have a strong balance sheet -- and you'll see we've actually slipped into slight net debt this time around. There's nothing particularly bad about that, it just means we're investing in things that are hopefully getting us a much better return, but we've still got a relatively strong balance sheet. That means we can continue to invest in business initiatives to support what we're trying to do in the broader business, as well as being able to take on acquisitions where we think they make sense, and that helps us build scale and diversify risk.”


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIP:AU A$0.77 AUD 0.00

SIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SIP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SIP Industry Range
Price/Earnings 17.5x
Price/Sales 0.2x
Price/Book 1.4x
Price/Cash Flow 14.4x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at